PMID-19777399 – Tesofensine Monoamine Reuptake Inhibitor Review
Hansen DL, Astrup A. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2009;10(10):1105-1112.
Quick Reference
| Property | Value |
|---|---|
| PMID | 19777399 |
| Year | 2009 |
| Journal | Current Opinion in Investigational Drugs |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review) |
| Peptide(s) Studied | Tesofensine |
Key Findings
- Tesofensine is a triple monoamine reuptake inhibitor (SNDRI) blocking serotonin, norepinephrine, and dopamine transporters
- Originally developed as NS-2330 for Parkinson's disease and Alzheimer's disease by NeuroSearch A/S
- Unexpected weight loss observed in CNS disease trials led to repositioning as an anti-obesity agent
- Mechanism of appetite suppression involves enhancement of satiety signaling via all three monoamine pathways
- At the 0.5 mg dose, efficacy potentially double that of then-approved anti-obesity drugs
- Main safety concern: cardiovascular effects (heart rate increase, blood pressure)
Study Design
Comprehensive narrative review covering preclinical pharmacology, clinical development history, Phase 2 efficacy and safety data, and comparison with existing anti-obesity agents.
Limitations
- Review article; no original data
- Published before Phase 3 decisions were made
- Industry-adjacent perspective
Clinical Relevance
Provides the most comprehensive overview of tesofensine's pharmacology and clinical positioning as of 2009. Important for understanding why the drug was never brought to Phase 3 in Western markets — the cardiovascular safety signal (heart rate increase) at efficacious doses remained a regulatory concern. Also documents the serendipitous discovery of its anti-obesity effects during CNS disease trials.
Related
#research #narrative-review #tesofensine #evidence-level-V